Categories: News

TRACON to Report First Quarter 2022 Financial Results and Corporate Update on May 11, 2022

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SAN DIEGO, May 04, 2022 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States, announced today that it will report its first quarter 2022 financial and operating results after the close of U.S. financial markets on Wednesday, May 11, 2022. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.

Conference call and webcast:
Date: May 11, 2022
Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)
Dial-in: (855) 779-9066 (Domestic) or (631) 485-4859 (International)
Passcode: 8178208
Via web: www.traconpharma.com; “Events and Presentations” section within the “Investors” section

A replay of the webcast will be available for 60 days on the website.

About TRACON

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States. To learn more about TRACON and its product pipeline, visit TRACON’s website at www.traconpharma.com.

Company Contact: Investor Contact:
Mark Wiggins Brian Ritchie
Chief Business Officer LifeSci Advisors LLC
(858) 251-3492 (212) 915-2578
mwiggins@traconpharma.com britchie@lifesciadvisors.com

Staff

Recent Posts

Brainomix Appoints Khush F. Mehta as Chair to Support Global Expansion and Commercial Growth

OXFORD, England and CHICAGO, May 21, 2025 /PRNewswire/ -- Brainomix, a global leader in AI-powered imaging…

32 minutes ago

The 10,000 Brains Project Launches the “Path-ND” Digital Brain Banking Program to Transform Neurodegenerative Disease Research

Funding from the Kissick Family Foundation Expands Frontotemporal Dementia Data; New Partnership with The Michael J. Fox Foundation Enhances Parkinson's Research OAKLAND, Calif., May…

7 hours ago

Medicus IT Names Roopak Manchanda as Executive Vice President of Community Health

Healthcare IT and community health leader to scale company's footprint and deepen impact in community-based…

7 hours ago

ESOC 2025: Combined oral contraceptives triple risk of cryptogenic stroke in young women, new study shows

HELSINKI, May 20, 2025 /PRNewswire/ -- New research presented today at the European Stroke Organisation…

7 hours ago

Codoxo Creates New “Point Zero” Category in Payment Integrity: Pre-Claim Provider Education Reduces Abrasion While Saving Payers $12-16 PMPY

Codoxo's Point Zero approach creates an entirely new space in payment integrity—before claims are ever…

7 hours ago

Bloom Burton & Co. Inc. Announces Exercise of Satellos Bioscience Inc. Warrants

Toronto, Ontario--(Newsfile Corp. - May 20, 2025) - Bloom Burton & Co. Inc. (Bloom Burton)…

12 hours ago